A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition Elizabeth I. BuchbinderAnita Giobbie-HurderPatrick A. Ott Brief Report 25 April 2023 Pages: 365 - 370
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth Arshak R. AlexanianHeidi Marie StoellingerAlfredo Quiñones-Hinojosa Brief Report 10 May 2023 Pages: 371 - 375
Prospective role of liquid biopsy for early screening in laryngeal cancer Xiao-yang GongHai-bing ChenXi Chen Correspondence 02 May 2023 Pages: 376 - 379
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors Anastasios StathisAnthony W. TolcherLillian L. Siu Research Open access 11 April 2023 Pages: 380 - 390
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy Nour AbuhadraRyan SunClinton Yam Research 12 April 2023 Pages: 391 - 401
Brigatinib pharmacokinetics in patients with chronic hepatic impairment Michael J. HanleyDavid KersteinNeeraj Gupta Research Open access 13 April 2023 Pages: 402 - 410
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients Takehiro TozukaNoriko YanagitaniMakoto Nishio Research 14 April 2023 Pages: 411 - 420
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors Arvind DasariErika P. HamiltonAndrew Scott Paulson Research Open access 19 April 2023 Pages: 421 - 430
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study Dong-Dong JiaYu XuTao Li Research Open access 24 April 2023 Pages: 431 - 437
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase Chan ZhangXinan ZhaoBaofeng Yu Research 25 April 2023 Pages: 438 - 452
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials Xiaoli LiYuyan LiuYuanyuan Liu Research 02 May 2023 Pages: 453 - 462
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients Xueyun TanSufei WangYang Jin Research Open access 04 May 2023 Pages: 463 - 472
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial Xiaoxue ZhuYanhua DingQingyu Wang Research 04 May 2023 Pages: 473 - 482
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles Toshiyuki TamaiMamoru Narukawa Research 10 May 2023 Pages: 483 - 492
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors Gerald S FalchookJasgit SachdevMelissa Johnson Research Open access 12 May 2023 Pages: 493 - 502
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors Yang LuoYing ChengBinghe Xu Research Open access 12 May 2023 Pages: 503 - 511
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis Takafumi YamamotoKazuyuki MizunoHiroki Kawashima Research 12 May 2023 Pages: 512 - 521
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies Li MaJuan MaHonggang Liu Research 17 May 2023 Pages: 522 - 531
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma Shiqi HuYaqin LiuWei Qiu Review 26 April 2023 Pages: 532 - 538
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies Danny N. KhalilIsabel Prieto González-AlboGerald A. Soff Correction 11 May 2023 Pages: 539 - 539